Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues

Abstract

Although Pembrolizumab-based immunotherapy has significantly improved lung cancer patient survival, many patients show variable efficacy and resistance development. A better understanding of the drug's action is needed to improve patient outcomes. Functional heterogeneity of the tumor microenvironment (TME) is crucial to modulating drug resistance; understanding of individual patients' TME that impacts drug response is hampered by lack of appropriate models. Lung organotypic tissue slice cultures (OTC) with patients' native TME procured from primary and brain-metastasized (BM) non-small cell lung cancer (NSCLC) patients were treated with Pembrolizumab and/or beta-glucan (WGP, an innate immune activator). Metabolic tracing with 13C6-Glc/13C5,15N2-Gln, multiplex immunofluorescence (mIF), and digital spatial profiling (DSP) were employed to interrogate metabolic and functional responses to Pembrolizumab and/or WGP. Primary and BM PD-1+ lung cancer OTC responded to Pembrolizumab and Pembrolizumab + WGP treatments, respectively. Pembrolizumab activated innate immune metabolism and functions in primary OTC, which were accompanied by tissue damage. DSP analysis indicated an overall decrease in immunosuppressive macrophages and T cells but revealed microheterogeneity in immune responses and tissue damage. Two TMEs with altered cancer cell properties showed resistance. Pembrolizumab or WGP alone had negligible effects on BM-lung cancer OTC but Pembrolizumab + WGP blocked central metabolism with increased pro-inflammatory effector release and tissue damage. In depth metabolic analysis and multiplex TME imaging of lung cancer OTC demonstrated overall innate immune activation by Pembrolizumab but heterogeneous responses in the native TME of a patient with primary NSCLC. Metabolic and functional analysis also revealed synergistic action of Pembrolizumab and WGP in OTC of metastatic NSCLC.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Excel spreadsheets of data used for tables and figures will be deposited at Dryad.

The following data sets were generated

Article and author information

Author details

  1. Teresa Fan

    University of Kentucky, LEXINGTON, United States
    For correspondence
    teresa.fan@uky.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7292-8938
  2. Richard M Higashi

    Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Huan Song

    Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Saeed Daneshmandi

    Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Angela L Mahan

    Baptist Health, Louisville, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Matthew S Purdom

    Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Therese J Bocklage

    Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Thomas A Pittman

    Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Daheng He

    Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Chi Wang

    Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Andrew N Lane

    Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, United States
    For correspondence
    andrew.lane@uky.edu
    Competing interests
    The authors declare that no competing interests exist.

Funding

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Surgical patients were consented for freshly resected tissue specimens under the approved IRB protocol (14-0288-F6A; 13-LUN-94-MCC) of the University of Kentucky (UKy).

Copyright

© 2021, Fan et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,395
    views
  • 214
    downloads
  • 21
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Teresa Fan
  2. Richard M Higashi
  3. Huan Song
  4. Saeed Daneshmandi
  5. Angela L Mahan
  6. Matthew S Purdom
  7. Therese J Bocklage
  8. Thomas A Pittman
  9. Daheng He
  10. Chi Wang
  11. Andrew N Lane
(2021)
Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues
eLife 10:e69578.
https://doi.org/10.7554/eLife.69578

Share this article

https://doi.org/10.7554/eLife.69578

Further reading

    1. Cancer Biology
    Rui Vasco Simoes, Rafael Neto Henriques ... Noam Shemesh
    Research Article

    Glioblastomas are aggressive brain tumors with dismal prognosis. One of the main bottlenecks for developing more effective therapies for glioblastoma stems from their histologic and molecular heterogeneity, leading to distinct tumor microenvironments and disease phenotypes. Effectively characterizing these features would improve the clinical management of glioblastoma. Glucose flux rates through glycolysis and mitochondrial oxidation have been recently shown to quantitatively depict glioblastoma proliferation in mouse models (GL261 and CT2A tumors) using dynamic glucose-enhanced (DGE) deuterium spectroscopy. However, the spatial features of tumor microenvironment phenotypes remain hitherto unresolved. Here, we develop a DGE Deuterium Metabolic Imaging (DMI) approach for profiling tumor microenvironments through glucose conversion kinetics. Using a multimodal combination of tumor mouse models, novel strategies for spectroscopic imaging and noise attenuation, and histopathological correlations, we show that tumor lactate turnover mirrors phenotype differences between GL261 and CT2A mouse glioblastoma, whereas recycling of the peritumoral glutamate-glutamine pool is a potential marker of invasion capacity in pooled cohorts, linked to secondary brain lesions. These findings were validated by histopathological characterization of each tumor, including cell density and proliferation, peritumoral invasion and distant migration, and immune cell infiltration. Our study bodes well for precision neuro-oncology, highlighting the importance of mapping glucose flux rates to better understand the metabolic heterogeneity of glioblastoma and its links to disease phenotypes.

    1. Cancer Biology
    2. Medicine
    Patrick Brandt, Dawayne Whittington ... Rebekah L Layton
    Research Article

    A doctoral-level internship program was developed at the University of North Carolina at Chapel Hill with the intent to create customizable experiential learning opportunities for biomedical trainees to support career exploration, preparation, and transition into their postgraduate professional roles. We report the outcomes of this program over a 5-year period. During that 5-year period, 123 internships took place at over 70 partner sites, representing at least 20 academic, for-profit, and non-profit career paths in the life sciences. A major goal of the program was to enhance trainees’ skill development and expertise in careers of interest. The benefits of the internship program for interns, host/employer, and supervisor/principal investigator were assessed using a mixed-methods approach, including surveys with closed- and open-ended responses as well as focus group interviews. Balancing stakeholder interests is key to creating a sustainable program with widespread support; hence, the level of support from internship hosts and faculty members were the key metrics analyzed throughout. We hypothesized that once a successful internship program was implemented, faculty culture might shift to be more accepting of internships; indeed, the data quantifying faculty attitudes support this. Furthermore, host motivation and performance expectations of interns were compared with results achieved, and this data revealed both expected and surprising benefits to hosts. Data suggests a myriad of benefits for each stakeholder group, and themes are cataloged and discussed. Program outcomes, evaluation data, policies, resources, and best practices developed through the implementation of this program are shared to provide resources that facilitate the creation of similar internship programs at other institutions. Program development was initially spurred by National Institutes of Health pilot funding, thereafter, successfully transitioning from a grant-supported model, to an institutionally supported funding model to achieve long-term programmatic sustainability.